摘要
目的观察中晚期非小细胞肺癌患者采用化疗联合树突细胞-细胞因子诱导杀伤细胞(DC-CIK)免疫治疗的临床效果。方法选择2013年4月—2016年1月收治的中晚期非小细胞肺癌患者78例,按治疗方法分为观察组39例(紫杉醇+顺铂化疗联合DC-CIK细胞免疫治疗)和对照组39例(单纯紫杉醇+顺铂化疗)。采用酶联免疫吸附法检测血清肿瘤标志物细胞角蛋白19血清片段211(CYFRA211)、癌胚抗原(CEA)、癌抗原125(CA125)的表达。采用流式细胞术检测外周血T淋巴细胞亚群、CIK细胞及Treg细胞的数量和比例,采用实体瘤疗效评价标准评估临床疗效,采用卡氏功能状态评分评估生存质量改善情况。结果治疗后两组血清CYFRA211、CEA和CA125水平明显低于治疗前(P<0.05),且观察组明显低于对照组(P<0.05)。治疗后对照组CD3+、CD4+、CD8+、CIK细胞的阳性细胞率明显低于治疗前(P<0.05),Treg细胞的阳性细胞率明显高于治疗前(P<0.05)。治疗后观察组CD3+、CD4+、CD8+、CIK细胞的阳性细胞率明显高于治疗前和对照组(P<0.05),Treg细胞的阳性细胞率明显低于治疗前和对照组(P<0.05)。观察组生活质量提高率、有效率和疾病控制率明显高于对照组(P<0.05)。结论化疗联合DC-CIK细胞免疫能提高中晚期非小细胞肺癌患者的临床治疗效果,并且能显著改善患者的免疫功能和生活质量。
Objective To observe clinical effect of chemotherapy combined with dendritic cells cytokine-induced killer cells （DC-CIK） immunotherapy in treatment of patients with middle-advanced non-small cell lung carcinoma （NSCLC）. Methods A total of 78 patients with middle-advanced NSCLC admitted during April 2013 and January 2016 were divided into observation group （n = 39, treated with Paclitaxel ＋ Cisplatin chemotherapy combined with DC-CIK immunotherapy） and control group （n = 39, only treated with Paclitaxel ＋ Cisplatin chemotherapy） according to treat- ment methods. Serum tumor markers of cytokeratin 19 fragment 211 （CYFRA211）, carcinoembryonic antigen （CEA） and cancer antigen 125 （CA125） expressions were detected by enzyme-linked immunosorbent assay. Absolute numbers and percentages of T lymphocyte subsets, CIK cells and Treg cells in peripheral blood were detected by flow cytometry. Clinical effect was evaluated by response evaluation criteria in solid tumors. Improvement condition of life quality was e- valuated by Karnofsky performance status scale. Results After treatment, serum CYFRA211, CEA and CA125 levels were significantly lower than those before treatment in the two groups （ P 〈 O.05 ）, and the levels in observation group were significantly lower than those in control group （ P 〈 O. 05 ）. After treatment, the positive cell rates of CD3 ＋ , CD4 ＋ , CD8 ＋ and CIK cells were significantly lower （ P 〈 0. 05 ）, while positive cell rate of Treg cells was significantly higher than those before treatment in control group （P 〈 O. 05）. After treatment, in observation group, positive cell rates of CD3 ＋ , CD4 ＋ , CD8 ＋ and CIK cells were significantly higher （P 〈 0. 05 ）, while positive cell rate of Treg cells was significantly lower than those before treatment in the same group and in control group （P 〈 0. 05 ）. Improvement and ef- fective rates for quality of life and disease control rate in observation group were signlfieantly higher t
作者
王晓辉
马俊
张俊
惠玲
WANG Xiao-hui MA Jun ZHANG Jun HUI Ling(Department of Medical Experiment Key Lab of Stem Cells and Genetaceutical of Gansu Province, Lanzhou General Hospital of Lanzhou Military Area Command, Lanzhou 730050, Chin)
出处
《解放军医药杂志》
CAS
2017年第9期26-30,共5页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
甘肃省科技重大专项资助项目(1302FKDA039)
关键词
癌
非小细胞肺
细胞因子诱导杀伤细胞
树突细胞
免疫疗法
Carcinoma, non-small-cell lung
Cytokine-induced killer cells
Dendritic cells
Immunotherapy
